rex4 Antibody

What is REXO4/REX4 and what cellular functions does it serve?

REXO4 (also known as REX4) is the RNA exonuclease 4 homolog, originally identified in Saccharomyces cerevisiae. It functions as an RNA processing enzyme with a calculated molecular weight of 47 kDa (422 amino acids), though it typically appears as a 47-50 kDa band in experimental detection systems . As an RNA exonuclease, REXO4 plays crucial roles in RNA metabolism, potentially including RNA degradation, processing, and quality control mechanisms. The protein is encoded by the REXO4 gene (Gene ID: 57109) and has the UniProt accession number Q9GZR2 . Understanding REXO4's cellular functions provides context for research applications of antibodies targeting this protein.

What applications are REXO4 antibodies validated for in research contexts?

REXO4 antibodies have been extensively validated for multiple research applications, with specific protocols established for each technique:

For optimal results, researchers should always conduct preliminary titration experiments to determine the ideal antibody concentration for their specific experimental system and sample type .

How should REXO4 antibody samples be stored to maintain reactivity?

Proper storage of REXO4 antibodies is critical for maintaining their specificity and sensitivity in experimental applications. The recommended storage conditions include:

• Temperature: Store at -20°C for long-term preservation of antibody activity .

• Buffer composition: Most commercial REXO4 antibodies are supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 .

• Stability: When stored properly, antibodies remain stable for at least one year after shipment .

• Aliquoting: For the standard storage temperature of -20°C, aliquoting is generally unnecessary, which simplifies laboratory handling procedures .

• Special considerations: Some preparations (particularly smaller 20μl sizes) may contain 0.1% BSA as a stabilizer .

Adhering to these storage guidelines ensures consistent antibody performance across experimental replicates, reducing technical variability in research results.

What controls should be included when using REXO4 antibodies in validation experiments?

Robust experimental design for REXO4 antibody applications requires comprehensive controls to ensure result validity:

For Western Blot applications:

• Positive controls: Include lysates from HeLa, HepG2, or Jurkat cells, which have been validated to express detectable levels of REXO4 protein .

• Negative controls: Consider knockdown/knockout verification using published REXO4 KD/KO systems referenced in multiple publications .

• Loading controls: Standard housekeeping proteins should be probed in parallel to normalize protein loading.

• Molecular weight verification: Confirm detection at the expected 47-50 kDa range for REXO4 .

For Immunohistochemistry:

• Tissue selection: Human testis tissue provides a reliable positive control for REXO4 expression .

• Antigen retrieval comparison: Verify results using both TE buffer (pH 9.0) and citrate buffer (pH 6.0) methods to determine optimal conditions .

• Isotype controls: Include rabbit IgG isotype controls at equivalent concentrations to assess non-specific binding .

For Immunofluorescence:

• Cellular localization controls: Compare observed localization patterns with expected subcellular distribution of REXO4.

• Co-localization studies: Consider co-staining with markers for relevant subcellular compartments.

These control strategies enhance confidence in experimental findings and support the specificity of the antibody for its intended target.

How should optimization of REXO4 antibody dilutions be approached for different experimental systems?

Optimization of REXO4 antibody dilutions should follow a systematic approach:

• Initial screening: Begin with the manufacturer's recommended dilution ranges (WB: 1:1000-1:4000; IHC: 1:20-1:200; IF/ICC: 1:400-1:1600) .

• Serial dilution testing: Prepare a logarithmic series of dilutions spanning the recommended range and slightly beyond to identify the optimal signal-to-noise ratio.

• Sample-specific considerations: Different cell lines and tissue types may require distinct antibody concentrations. For example:

  • For WB applications with HeLa, HepG2, or Jurkat cells, start with a 1:2000 dilution .

  • For IHC with human testis tissue, begin optimization at 1:100 dilution .

• Protocol adaptation: Buffer composition, incubation time, and temperature may require adjustment based on initial results.

• Validation across preparations: If changing antibody lots, brief re-optimization is recommended to maintain consistency.

The manufacturerʼs guidelines emphasize that "this reagent should be titrated in each testing system to obtain optimal results," acknowledging the importance of experimental system-specific optimization .

What are the recommended antigen retrieval methods for REXO4 immunohistochemistry?

Effective antigen retrieval is critical for successful REXO4 immunohistochemistry. The following methods have been validated:

Primary recommendation:

• Buffer: TE buffer at pH 9.0

• This alkaline pH buffer system has shown superior results for exposing REXO4 epitopes in formalin-fixed, paraffin-embedded tissues.

Alternative method:

• Buffer: Citrate buffer at pH 6.0

• This traditional retrieval system may be preferred in certain tissue types or when comparing results with historical data using acidic retrieval methods.

Optimization recommendations:

• Compare both methods in parallel during protocol development

• Assess background staining, signal intensity, and specificity with each method

• Consider tissue-specific variables that may influence epitope accessibility

• Document optimal heating times and temperatures for reproducibility

The selection between these methods should be based on empirical testing with the specific tissue samples under investigation, as different tissue fixation procedures may influence epitope accessibility.

How can REXO4 antibody specificity be confirmed through knockout/knockdown validation approaches?

Confirming REXO4 antibody specificity through genetic manipulation represents a gold standard validation approach. The literature indicates multiple published knockout/knockdown verification methods:

• Genetic knockdown validation strategies:

  • Published literature includes at least two studies utilizing REXO4 knockdown approaches for antibody validation .

  • siRNA or shRNA targeting REXO4 can be employed, followed by Western blot analysis to confirm reduced or absent signal at the expected 47-50 kDa molecular weight.

  • Quantitative comparison between control and knockdown samples should show significant signal reduction proportional to knockdown efficiency.

• CRISPR/Cas9 knockout validation:

  • Complete knockout of REXO4 provides the most stringent specificity control.

  • When designing knockout strategies, consider potential embryonic lethality if REXO4 serves essential cellular functions.

  • Verification should include genomic sequencing confirmation alongside antibody testing.

• Documentation requirements:

  • Clear presentation of both control and KD/KO samples run in adjacent lanes

  • Loading controls to normalize protein amounts

  • Quantification of signal reduction relative to transcript/protein reduction

The presence of multiple published KD/KO validation studies supports the specificity of commercially available REXO4 antibodies and provides methodological frameworks for laboratory-specific validation .

What cross-reactivity considerations exist for REXO4 antibodies across species?

Cross-species reactivity is an important consideration when selecting REXO4 antibodies for comparative studies:

When designing cross-species experiments, researchers should consider:

These considerations are particularly important for evolutionary biology studies or when translating findings between model organisms and human systems.

How can researchers troubleshoot weak or absent signals in Western blot applications of REXO4 antibodies?

When encountering suboptimal signals with REXO4 antibodies in Western blot applications, implement this systematic troubleshooting approach:

• Sample preparation optimization:

  • Verify protein extraction efficiency from different cell types (HeLa, HepG2, and Jurkat cells are known to express detectable REXO4 levels) .

  • Evaluate various lysis buffers, particularly for nuclear proteins.

  • Include protease inhibitors to prevent target degradation.

• Protein loading considerations:

  • Increase total protein loading (20-40 μg recommended for detection of less abundant proteins).

  • Verify protein transfer efficiency through reversible staining.

• Antibody optimization:

  • Increase antibody concentration within the recommended range (1:1000-1:4000) .

  • Extend primary antibody incubation (overnight at 4°C).

  • Test alternative blocking agents (5% BSA vs. 5% non-fat dry milk).

• Detection system enhancement:

  • Employ high-sensitivity detection reagents for low abundance targets.

  • Increase exposure time for chemiluminescent detection.

  • Consider more sensitive detection methods (e.g., fluorescent secondary antibodies).

• Specific considerations for REXO4:

  • Expected molecular weight range is 47-50 kDa .

  • Signal may be tissue/cell-type dependent, with established detection in HeLa, HepG2, and Jurkat cells .

  • Compare results with published WB applications (at least 3 publications have successfully utilized REXO4 antibodies for WB) .

Implementation of these methodological refinements should resolve most detection challenges in Western blot applications.

How does REXO4 compare structurally and functionally to other RNA exonuclease family members?

REXO4 (RNA exonuclease 4 homolog) belongs to the broader family of RNA exonucleases but possesses distinctive characteristics:

Structural comparison:

• REXO4 consists of 422 amino acids with a calculated molecular weight of 47 kDa, though it typically appears as a 47-50 kDa protein in experimental systems .

• Unlike some family members with multiple functional domains, REXO4's core exonuclease domain is its primary structural feature.

• The protein's UniProt ID (Q9GZR2) allows researchers to access its complete sequence and structural information .

Functional differentiation:

• REXO4's evolutionary conservation from yeast (S. cerevisiae) to humans suggests fundamental roles in RNA metabolism .

• Unlike the well-characterized RECQL4 helicase (sometimes confused with REXO4 due to naming similarity), REXO4 functions specifically in RNA processing rather than DNA repair mechanisms .

• Current research suggests specialized functions in RNA quality control pathways, distinguishing it from more general RNA degradation enzymes.

Investigation methods:

• Comparative immunoprecipitation studies using optimized protocols (0.5-4.0 μg antibody per 1.0-3.0 mg total protein) can help identify interaction partners specific to REXO4 versus other family members .

• Subcellular localization studies using immunofluorescence (recommended dilution 1:400-1:1600) provide insights into compartment-specific functions .

Future research directions should focus on defining the substrate specificity and regulatory mechanisms that distinguish REXO4 from related exonucleases in the cellular RNA processing machinery.

What considerations should researchers address when integrating REXO4 antibodies in multi-parameter imaging studies?

Multi-parameter imaging studies incorporating REXO4 antibodies require careful planning to achieve robust, interpretable results:

• Antibody compatibility considerations:

  • The rabbit IgG isotype of commonly available REXO4 antibodies (e.g., 18890-1-AP) must be considered when designing multi-labeling panels .

  • Secondary antibody selection should avoid cross-reactivity with other primary antibodies in the panel.

  • For multi-species primary antibodies, highly cross-adsorbed secondary antibodies are recommended.

• Spectral separation optimization:

  • When selecting fluorophores for REXO4 co-detection, consider spectral separation to minimize bleed-through.

  • Sequential scanning approaches may be necessary for confocal microscopy applications.

  • Controls should include single-color samples to establish proper compensation settings.

• Protocol adaptations:

  • For IF/ICC applications, the recommended dilution range of 1:400-1:1600 provides a starting point for optimization in multiplex settings .

  • Antibody incubation sequence may need adjustment when combining surface and intracellular markers.

  • Standard protocols may require modification when combining with specialized techniques like FISH or proximity ligation assays.

• Validation requirements:

  • Positive controls should include HeLa cells, which have been validated for REXO4 detection by IF/ICC .

  • Comparison with published IF studies (at least one publication has successfully employed REXO4 antibodies for IF) provides methodological guidance .

Multi-parameter imaging approaches can reveal important insights about REXO4's interactions with other cellular components, providing functional context beyond single-marker detection.

How can researchers evaluate the developability profile of novel anti-REXO4 antibodies for advanced research applications?

Evaluating developability of novel anti-REXO4 antibodies requires systematic assessment across multiple parameters, drawing from established antibody development frameworks:

• Initial affinity and specificity screening:

  • Implement an integrated high-throughput developability workflow early in the antibody candidate screening process .

  • Evaluate a diverse panel of candidates representing multiple human germline V-genes to ensure robust selection .

  • Document specificity through complementary methods (Western blot, immunoprecipitation, and immunofluorescence) as demonstrated with existing REXO4 antibodies .

• Biophysical property assessment:

  • Apply the "red flag" descriptor framework, focusing on biophysical characteristics in the bottom 10th percentile of clinical antibodies .

  • Evaluate stability parameters predictive of long-term performance in research applications.

  • Document thermal stability, aggregation propensity, and solubility profiles.

• Sequence engineering optimization:

  • Identify and address sequence liabilities that could compromise antibody performance .

  • Consider scaffold selection from well-established clinical antibodies with demonstrated developability .

  • Implement mutagenesis to remove post-translational modification sites or disrupt problematic hydrophobic/charged patches .

• Comparative validation against existing standards:

  • Benchmark performance against established anti-REXO4 antibodies in terms of sensitivity, specificity, and application versatility .

  • Document improvements in problematic performance areas.

This iterative process of analytical characterization and engineering (as illustrated in Figure 1 of reference ) ensures that only robust antibody molecules progress to advanced research applications, reducing failure rates due to poor affinity or developability issues .

What buffer systems provide optimal results for REXO4 immunohistochemistry in different tissue types?

Buffer selection for REXO4 immunohistochemistry significantly impacts staining quality and requires tissue-specific optimization:

Primary recommendation:

• TE buffer at pH 9.0 has demonstrated superior results for REXO4 detection in human testis tissue .

• This alkaline pH buffer system enhances epitope retrieval in formalin-fixed, paraffin-embedded tissues.

Alternative method:

• Citrate buffer at pH 6.0 serves as an effective alternative when alkaline conditions are contraindicated .

• Some tissue types may show reduced background staining with this more acidic retrieval system.

Tissue-specific considerations:

• Human testis tissue has been validated with both buffer systems, with TE buffer (pH 9.0) showing preferable results .

• For human gliomas and kidney tissue, similar buffer systems have been effective for related proteins, suggesting potential transferability of protocols .

Optimization methodology:

• Conduct parallel testing of both buffer systems on identical tissue sections

• Evaluate signal intensity, background staining, and cellular localization specificity

• Document optimal heating conditions (temperature, duration, method)

• Consider tissue fixation history as a variable affecting buffer performance

The manufacturer's recommendation to use TE buffer (pH 9.0) as the primary choice with citrate buffer (pH 6.0) as an alternative provides a validated starting point for protocol development .

What strategies can researchers employ to minimize batch-to-batch variability when using REXO4 antibodies in longitudinal studies?

Minimizing batch-to-batch variability is critical for longitudinal studies employing REXO4 antibodies:

• Antibody selection and procurement strategy:

  • Choose antibodies manufactured using standardized processes that ensure rigorous quality control .

  • Consider antibodies with published validation across multiple applications, suggesting reproducible performance .

  • When possible, reserve sufficient antibody from a single lot for the entire study duration.

• Reference standard development:

  • Create and preserve internal reference standards (cell lysates, tissue sections) from validated positive controls such as HeLa cells .

  • Include these standards in each experimental batch to normalize between-run variations.

  • Document signal intensity metrics for quantitative comparison across experimental batches.

• Protocol standardization:

  • Develop detailed standard operating procedures (SOPs) for each application.

  • Specify critical parameters including antibody dilution ranges (WB: 1:1000-1:4000; IHC: 1:20-1:200; IF/ICC: 1:400-1:1600) .

  • Implement automated systems where possible to reduce operator variability.

• Cross-batch validation:

  • When transitioning to new antibody lots, perform side-by-side comparison with previous lots.

  • Adjust dilutions or protocols as necessary to maintain equivalent signal characteristics.

  • Document all validation experiments in a structured database for reference.

• Storage and handling consistency:

  • Maintain consistent storage conditions (-20°C) as specified by manufacturers .

  • Implement standardized aliquoting procedures to minimize freeze-thaw cycles.

  • Document storage duration for each antibody lot used in the study.

These strategies collectively minimize technical variability, ensuring that observed differences represent true biological changes rather than methodology artifacts.

How can researchers adapt REXO4 antibody protocols for automated high-throughput screening platforms?

Adapting REXO4 antibody protocols for automated high-throughput screening requires systematic optimization of multiple parameters:

• Antibody dilution optimization for automated systems:

  • Initial screening should test a broader range around manufacturer recommendations (WB: 1:1000-1:4000; IHC: 1:20-1:200; IF/ICC: 1:400-1:1600) .

  • For automated systems, consider increasing antibody concentration by 20-30% to compensate for shorter incubation times.

  • Document optimal signal-to-noise ratios across the dilution range for the specific automated platform.

• Incubation parameter adjustments:

  • Standard protocols may require modification to accommodate fixed incubation times in automated systems.

  • Temperature adjustments can compensate for reduced incubation periods.

  • Optimize primary antibody incubation conditions while maintaining detection specificity.

• Plate/slide format considerations:

  • Validate REXO4 detection in high-density plate formats before full-scale implementation.

  • Assess edge effects and implement appropriate controls to normalize position-dependent variations.

  • For tissue microarrays, verify detection consistency across the array, particularly with human testis tissue as a positive control .

• Quality control implementation:

  • Incorporate positive controls (HeLa, HepG2, or Jurkat cells for REXO4) in standardized positions .

  • Develop automated image analysis algorithms to quantify REXO4 signal characteristics.

  • Implement statistical process control methods to monitor system performance across experimental batches.

• Validation requirements:

  • Cross-validate automated and manual protocols on identical samples.

  • Document equivalence or systematic differences between approaches.

  • Establish acceptance criteria for high-throughput screening quality metrics.

The implementation of these methodological adaptations should facilitate reliable REXO4 detection in high-throughput contexts while maintaining the specificity and sensitivity achieved in standard protocols.